X

Trial Profile

A single centre, randomised controlled, open label study of rituximab as induction therapy in kidney transplantation

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Daclizumab
Indications Renal transplant rejection
Focus Pharmacogenomic; Therapeutic Use
Acronyms Rituxicam2005

Most Recent Events

30 Aug 2009 Tolerability results have been reported at the 14th Congress of the European Society for Organ Transplantation.
18 Jun 2009 Results reported in the New England Journal of Medicine.
03 Jun 2009 Status changed from recruiting to discontinued; results reported at ATC 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com